hrp0094p2-260 | Growth hormone and IGFs | ESPE2021
Thomas Muriel
, Casteels Kristina
, Rochtus Anne
, van der Straaten Saskia
, Van Aken Sara)
, Fudvoye Julie
, Boros Emese
, Dotremont Hilde
, Vanbesien Jesse
, Mouraux Thierry
, Chivu Olimpia
, Logghe Karl
, Reynaert Nele
, Massa Guy
, Depoorter Sylvia
, Klink Daniel
, Becker Marianne
, Lysy Philippe
, De Schepper Jean
,
Background and Aim: Recombinant growth hormone (GH) is reimbursed for the treatment of short stature (<-2.5 Z-score) in children born small for gestational age (SGA) without postnatal growth, aged ≥ 4 years with a height Z-score >1 below mid-parental height (MPH). We wanted to determine the current GH prescribing practices by pediatric endocrinologists (PE) for SGA related short stature and document the percentages of treated children at risk for...